Verum Partners’s Pfizer PFE Stock Holding History

Verum Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,861	Closed	-$252K	–	146
2023 Q2	$252K	Buy	+6,861	New	+$267K	0.23%	79
2023 Q1	–	Sell	-5,492	Closed	-$281K	–	70
2022 Q4	$281K	Buy	+5,492	New	+$263K	0.35%	53

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verum Partners's PFE Position: Q3 2023 in Review

Verum Partners sold out of Pfizer (PFE) in Q3 2023, closing a stake of 6,861 shares — an estimated $252K sold.

Verum Partners first reported a position in PFE in Q4 2022 and held it in 2 quarters. The position peaked at $281K in Q4 2022. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Verum Partners reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Verum Partners sold 6,861 Pfizer shares in Q3 2023, an estimated $252K.
Verum Partners first reported a position in Pfizer in Q4 2022 and held it in 2 quarters.
Verum Partners's Pfizer position peaked at $281K in Q4 2022.
2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Verum Partners's 13F filing for Q3 2023, filed 10 Oct 2023.